Annals of Surgical Oncology

, Volume 18, Issue 3, pp 720–725 | Cite as

Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution

  • Roberta Sanfilippo
  • Rosalba Miceli
  • Federica Grosso
  • Marco Fiore
  • Elisa Puma
  • Elisabetta Pennacchioli
  • Marta Barisella
  • Claudia Sangalli
  • Luigi Mariani
  • Paolo G. Casali
  • Alessandro Gronchi
Bone and Soft Tissue Sarcomas

Abstract

Background

First described in 1977, myxofibrosarcoma is one of the most common sarcoma subtypes of the elderly. Until some years ago, myxofibrosarcoma was diagnosed as “myxoid malignant fibrous histiocytoma.” The aim of this retrospective case series analysis was to investigate prognostic factors and the clinical outcome of a cohort of patients with myxofibrosarcoma treated at a single institution.

Methods

We reviewed 158 patients with localized myxofibrosarcoma who underwent surgery at the Istituto Nazionale Tumori of Milan, Italy, over 15 years. Local recurrence, distant metastases, and survival were analyzed.

Results

One hundred twenty patients had primary tumors, while 38 patients had locally recurrent tumors. Five-year overall survival was 77%. Tumor size, grade, and margins were statistically significant predictors of survival. Five-year local recurrence and distant metastases rate were 18% and 15%, respectively. Surgical margins were the only statistically significant prognosticator of local relapses. Patients treated with radiotherapy had the same prognosis as nontreated patients, but likely they had worse local presentations. The histological grade correlated with distant recurrences but not with local relapses. The value of adjuvant chemotherapy could not be determined.

Conclusions

Patients with myxofibrosarcoma have a better disease-specific survival than other sarcoma subtypes, but also a higher local relapse rate. This is likely related to the peculiar local growth pattern of these tumors. Adequate surgery should be pursued, while the role of adjuvant therapies need to be investigated.

References

  1. 1.
    Angervall L, Kindblom LG, Merck C, et al. Myxofibrosarcoma. A study of 30 cases. Acta Pathol Microbiol Scand. 1977;85A:127–40.Google Scholar
  2. 2.
    Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press; 2002. p. 102–3.Google Scholar
  4. 4.
    Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996;20:391–405.PubMedCrossRefGoogle Scholar
  5. 5.
    Merck C, Angervall L, Kindblom LG, et al. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastichistiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand Suppl. 1983;282:1–40.PubMedGoogle Scholar
  6. 6.
    Hisaoka M, Morimitsu Y, Hashimoto H, et al. Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas. Am J Surg Pathol. 1999;23:1480–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Meis-Kindblom JM, Sjögren H, Kindblom LG, et al. Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Arch. 2001;439:141–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Fletcher CDM, Gustafson P, Rydholm A, et al. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J Clin Oncol. 2001;19:3045–50.PubMedGoogle Scholar
  9. 9.
    Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251:506–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Trojani M, Contesso G, Coindre JM, et al. Soft tissue sarcomas of adults: study of pathological prognostic variables and definition of a histopathologic grading system. Int J Cancer. 1984;33:37–42.PubMedCrossRefGoogle Scholar
  11. 11.
    Marubini E, Valsecchi MG. Analysing survival data for clinical trials and observational studies. Chichester, UK: Wiley; 1995.Google Scholar
  12. 12.
    Stojadinovic A, Leung DH, Hoos A, et al. Analysis of the prognostic significance of microscopic margins in 2084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235:424–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft tissue sarcoma treated with conservation surgery and radiation therapy. An analysis of 1225 patients. Cancer. 2003;97:2530–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Gronchi A, Casali PG, Mariani L, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol. 2005;23:96–104.PubMedCrossRefGoogle Scholar
  15. 15.
    Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–47.PubMedGoogle Scholar
  16. 16.
    Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–81.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Roberta Sanfilippo
    • 1
  • Rosalba Miceli
    • 2
  • Federica Grosso
    • 1
    • 6
  • Marco Fiore
    • 3
  • Elisa Puma
    • 1
  • Elisabetta Pennacchioli
    • 3
  • Marta Barisella
    • 4
  • Claudia Sangalli
    • 5
  • Luigi Mariani
    • 2
  • Paolo G. Casali
    • 1
  • Alessandro Gronchi
    • 3
  1. 1.Department of Cancer MedicineIstituto Nazionale TumoriMilanItaly
  2. 2.Unit of Clinical Epidemiology and Trial OrganizationIstituto Nazionale TumoriMilanItaly
  3. 3.Department of SurgeryIstituto Nazionale TumoriMilanItaly
  4. 4.Department of PathologyIstituto Nazionale TumoriMilanItaly
  5. 5.Department of RadiotherapyIstituto Nazionale TumoriMilanItaly
  6. 6.General HospitalAlessandriaItaly

Personalised recommendations